Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
651
mi
from 91732
Albuquerque, NM
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
651
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
Status: Enrolling
Updated:  12/31/1969
New Mexico Cancer Care Associates
690
mi
from 91732
Santa Fe, NM
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
Status: Enrolling
Updated: 12/31/1969
New Mexico Cancer Care Associates
690
mi
from 91732
Santa Fe, NM
Click here to add this to my saved trials
Tumor Specific Plasma DNA
Tumor Specific Plasma DNA
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Tumor Specific Plasma DNA
Tumor Specific Plasma DNA
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Anchorage Oncology Centre
2341
mi
from 91732
Anchorage, AK
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Anchorage Oncology Centre
2341
mi
from 91732
Anchorage, AK
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Katmai Oncology Group
2341
mi
from 91732
Anchorage, AK
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Katmai Oncology Group
2341
mi
from 91732
Anchorage, AK
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
2341
mi
from 91732
Anchorage, AK
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
2341
mi
from 91732
Anchorage, AK
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Bozeman Deaconess Hospital
885
mi
from 91732
Bozeman, MT
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Bozeman Deaconess Hospital
885
mi
from 91732
Bozeman, MT
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
840
mi
from 91732
Kennewick, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
840
mi
from 91732
Kennewick, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Skagit Valley Hospital
1015
mi
from 91732
Mount Vernon, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Skagit Valley Hospital
1015
mi
from 91732
Mount Vernon, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Olympic Medical Center
1008
mi
from 91732
Port Angeles, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Olympic Medical Center
1008
mi
from 91732
Port Angeles, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Group Health Cooperative
963
mi
from 91732
Redmond, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Group Health Cooperative
963
mi
from 91732
Redmond, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
954
mi
from 91732
Seattle, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
954
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Spokane Valley Cancer Center-Mission
939
mi
from 91732
Spokane, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Spokane Valley Cancer Center-Mission
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
MultiCare Tacoma General Hospital
922
mi
from 91732
Tacoma, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
MultiCare Tacoma General Hospital
922
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  12/31/1969
Wenatchee Valley Hospital and Clinics
930
mi
from 91732
Wenatchee, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 12/31/1969
Wenatchee Valley Hospital and Clinics
930
mi
from 91732
Wenatchee, WA
Click here to add this to my saved trials
Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer
Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer
Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates
Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
2129
mi
from 91732
Winston-Salem, NC
Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates
Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
2129
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Helen F. Graham Cancer Center
2347
mi
from 91732
Newark, DE
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Helen F. Graham Cancer Center
2347
mi
from 91732
Newark, DE
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
2184
mi
from 91732
Orlando, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
2184
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
IU Health Goshen Cancer Center
1819
mi
from 91732
Goshen, IN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
IU Health Goshen Cancer Center
1819
mi
from 91732
Goshen, IN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Massachusettes General Hospital
2578
mi
from 91732
Boston, MA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Massachusettes General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Weill Cornell -New York Presbyterian Hospital
2351
mi
from 91732
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Weill Cornell -New York Presbyterian Hospital
2351
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
2435
mi
from 91732
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
1762
mi
from 91732
Nashville, TN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Sammons Cancer Center
1225
mi
from 91732
Dallas, TX
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Sammons Cancer Center
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Cancer Center
961
mi
from 91732
Seattle, WA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Cancer Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz Medical Campus
825
mi
from 91732
Aurora, CO
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz Medical Campus
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Bayview Medical Center
2304
mi
from 91732
Baltimore, MD
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Bayview Medical Center
2304
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
1922
mi
from 91732
Atlanta, GA
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
2189
mi
from 91732
Chapel Hill, NC
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
W F Baptist Health
2125
mi
from 91732
Winston-Salem, NC
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
W F Baptist Health
2125
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
1881
mi
from 91732
Lexington, KY
Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Stereotactic Body Radiation Therapy for Post-chemoradiation Residual Disease in Stage II/III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Markey Cancer Center
1881
mi
from 91732
Lexington, KY
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Stereotactic Body Radiation Therapy for Post-chemoradiation Residual Disease in Stage II/III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Markey Cancer Center
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Wake Forest Cancer Center CCOP Research Base
mi
from 91732
Winston-Salem, NC
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Wake Forest Cancer Center CCOP Research Base
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Yale University
2486
mi
from 91732
New Haven, CT
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Yale University
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Northwest Georgia Oncology Center
1907
mi
from 91732
Marietta, GA
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Northwest Georgia Oncology Center
1907
mi
from 91732
Marietta, GA
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
2451
mi
from 91732
Mineola, NY
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials